Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 6, 2012, Pages

  Homma, Tsuyoshi ^a,b   Sonoda, Hiroko ^a   Manabe, Kenichi ^b   Arai, Kiyoshi ^b   Mizuno, Makoto ^b   Sada, Toshio ^b   Ikeda, Masahiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Angiotensin II; Angiotensin II type 1 receptor; Myocardial infarction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1A RECEPTOR; OLMESARTAN; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIORENAL SYNDROME; CELL INFILTRATION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; GENE; GLOMERULOSCLEROSIS; HEART FUNCTION; HEART INFARCTION; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MONONUCLEAR CELL; NEPHRECTOMY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; UPREGULATION;

EID: 84858177903     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00494.2011     Document Type: Article

References (56)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
2. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 80: 915-925, 2011.
3. Bagshaw SM, Cruz DN, Aspromonte N, Daliento L, Ronco F, Sheinfeld G, Anker SD, Anand I, Bellomo R, Berl T, Bobek I, Davenport A, Haapio M, Hillege H, House A, Katz N, Maisel A, Mankad S, McCullough P, Mebazaa A, Palazzuoli A, Ponikowski P, Shaw A, Soni S, Vescovo G, Zamperetti N, Zanco P, Ronco C; Acute Dialysis Quality Initiative Consensus Group. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 25: 1406-1416, 2010.
4. Bahiense-Oliveira M, Mattar AL, Malheiros DM, Woronik V. Interstitial expression of angiotensin II and AT1 receptor are increased in patients with progressive glomerulopathies. J Renin Angiotensin Aldosterone Syst 11: 158-164, 2010.
5. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326: 15-24, 2003.
6. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241, 2005.
7. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 87: 3C-9C, 2001.
8. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, De Gasparo M, Cooper ME. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13: 1773-1787, 2002.
9. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 298: R1089-R1097, 2010.
10. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL, Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux PL, Ruiz P. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 55: 99-108, 2010.
11. Dragun D, Tullius SG, Park JK, Maasch C, Lukitsch I, Lippoldt A, Gross V, Luft FC, Haller H. ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. Kidney Int 54: 590-602, 1998.
12. Eijkelkamp WB, de Graeff PA, van Veldhuisen DJ, van Dokkum RP, Gansevoort RT, de Jong PE, de Zeeuw D, Hillege HL. Effect of first myocardial ischemic event on renal function. Am J Cardiol 100: 7-12, 2007.
13. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119: 912-919, 2006.
14. Garg AX, Prasad GV, Thiessen-Philbrook HR, Ping L, Melo M, Gibney EM, Knoll G, Karpinski M, Parikh CR, Gill J, Storsley L, Vlasschaert M, Mamdani M; Donor Nephrectomy Outcomes Research (DONOR) Network. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation 86: 399-406, 2008.
15. Gonçalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, Zatz R. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 286: F945-F954, 2004.
16. Graciano ML, Cavaglieri Rde C, Dellê H, Dominguez WV, Casarini DE, Malheiros DM, Noronha IL. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 15: 1805-1815, 2004.
17. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460, 2007.
18. Hall JE. The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther 17: 8-17, 1991.
19. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62: 1402-1407, 2002.
20. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002.
21. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249: 519-526, 2001.
22. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24: 412-420, 2003.
23. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 105: 30A-35A, 2010.
24. Isoyama S, Grossman W, Wei JY. Effect of age on myocardial adaptation to volume overload in the rat. J Clin Invest 81: 1850-1857, 1988.
25. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 18: 1093-1102, 2007.
26. Kato A, Hishida A, Tanaka I, Komatsu K. Uninephrectomy prevents the ischemia-induced increase in renin activity. Nephron 75: 72-76, 1997.
27. Keeton TK, Pettinger WA, Campbell WB. The effects of altered sodium balance and adrenergic blockade on renin release induced in rats by angiotensin antagonism. Circ Res 38: 531-539, 1976.
28. Kim S, Sada T, Mizuno M, Ikeda M, Yano M, Miura K, Yamanaka S, Koike H, Iwao H. Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats. Hypertens Res 20: 133-142, 1997.
29. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636, 2001.
30. Miyata N, Park F, Li XF, Cowley AW Jr. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol Renal Physiol 277: F437-F446, 1999.
31. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 285: 181-188, 1995.
32. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161: 1679-1693, 2002.
33. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 298: F683-F691, 2010.
34. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
35. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110: 1859-1868, 2002.
36. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
37. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
38. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 121: 656-663, 2008.
39. Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59: 1626-1640, 2001.
40. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004.
41. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539, 2008.
42. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31: 703-711, 2010.
43. Sandmann S, Li J, Fritzenkötter C, Spormann J, Tiede K, Fischer JW, Unger T. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press 15: 116-128, 2006.
44. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 5: 1132-1140, 2010.
45. Schunkert H, Tang SS, Litwin SE, Diamant D, Riegger G, Dzau VJ, Ingelfinger JR. Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc Res 27: 731-735, 1993.
46. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38, 2003.
47. Sonoda H, Yokota-Ikeda N, Oshikawa S, Kanno Y, Yoshinaga K, Uchida K, Ueda Y, Kimiya K, Uezono S, Ueda A, Ito K, Ikeda M. Decreased abundance of urinary exosomal aquaporin-1 in renal ischemiareperfusion injury. Am J Physiol Renal Physiol 297: F1006-F1016, 2009.
48. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781, 2002.
49. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez M, Windt WA, van Veldhuisen DJ, de Graeff PA, de Zeeuw D. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 15: 3103-3110, 2004.
50. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 323: 85-93, 2007.
51. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 12: 205S-213S, 1999.
52. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Bohm M. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97: 418-431, 2008.
53. White WB. Angiotensin-converting enzyme inhibitors in the treatment of hypertension: an update. J Clin Hypertens (Greenwich) 9: 876-882, 2007.
54. Windt WA, Eijkelkamp WB, Henning RH, Kluppel AC, de Graeff PA, Hillege HL, Schäfer S, de Zeeuw D, van Dokkum RP. Renal damage after myocardial infarction is prevented by renin-angiotensinaldosterone-system intervention. J Am Soc Nephrol 17: 3059-3066, 2006.
55. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21, 2011.
56. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010.